Skip to main content

Table 2 Baseline characteristics according to the type of pancreatitis

From: Acute idiopathic pancreatitis is associated with more aggressive disease course in Crohn’s disease but not in ulcerative colitis

 

Crohn’s Disease (n = 29)

Ulcerative Colitis (n = 24)

Total (n = 53)

 

Idiopathic Pancreatitis

(n = 11)

Other causes of pancreatitis (n = 18)

P-value

Idiopathic Pancreatitis (n = 9)

Other causes of pancreatitis (n = 15)

P-value

Idiopathic Pancreatitis

(n = 20)

Other causes of pancreatitis (n = 33)

P-value

Duration of IBD (y)

26.76

(7.25–29.66)

17.95

(3.74–32.61)

0.97

9.92

(0.95–17.85)

19.01

(10.53–31.97)

0.18

11.58

(3.93–35.12)

19.01

(5.63–31.62)

0.33

Age (y)

46.29

(42.78–57.86)

56.38

(38.86–69.73)

0.61

37.25

(24.70-83.71)

52.53

(42.73–68.03)

0.77

46.00

(31.59–67.92)

52.53

(39.58–69.44)

0.48

Duration of hospitalization (d)

2.00

(1.75–2.75)

3.00

(2.00–4.00)

0.06

2.00

(2.00-5.50)

3.00

(2.00–5.00)

0.64

2.00

(2.00–4.00)

3.00

(2.00-4.25)

0.09

Female

6 (54.55%)

11 (61.11%)

0.73

7 (77.78%)

7 (46.67%)

0.13

13 (65.00%)

18 (54.55%)

0.45

Smoking

7 (63.64%)

11 (61.11%)

0.89

3 (33.33%)

8 (53.33%)

0.34

10 (50.00%)

19 (57.58%)

0.59

Biologics

3 (27.27%) ¶

5 (27.78%) †

0.98

1 (11.11%) ‡

3 (20.00%) §

0.57

4 (20.00%)

8 (24.24%)

0.72

Extra-intestinal manifestations

6 (54.55%)

7 (38.89%)

0.41

1 (11.11%)

5 (33.33%)

0.22

7 (35.00%)

12 (36.36%)

0.92

Recurrence

3 (27.27%)

4 (22.22%)

0.76

6 (66.67%)

1 (6.67%)

< 0.01

9 (45.00%)

5 (15.15%)

0.02

Number of AP episodes

1.00

(1.00–2.00)

1.00

(1.00-1.25)

0.76

2.00

(1.00–3.00)

1.00

(1.00–1.00)

< 0.01

1.00

(1.00–3.00)

1.00

(1.00–1.00)

0.02

  1. Abbreviations: IBD, Inflammatory Bowel Disease; y, years; d, days; AP, Acute Pancreatitis
  2. ¶ Two patients were on Remicade and one patient was on Vedolizumab
  3. † Three patients were on Adalimumab, One patient on Remicade, and one patient on 6-Mercaptopurine and Sulfasalazine
  4. ‡ One patient was on Remicade
  5. § Two patients were on 6-Mercaptopurine and one patient was on Azathioprine